Highlights

  • BlinkLab (ASX:BB1) reported developments during 2026.
  • In August 2026 BlinkLab described results from a European ADHD digital biomarker study, reporting sensitivity of 82% and specificity of 83% in that study.
  • In June 2026 BlinkLab announced a United States Patent relating to its remote neurobehavioural testing platform.
  • The November 18, 2026 share price was AUD 0.57, up 1.79%.

BlinkLab develops smartphone-based assessments that measure neurobehavioural responses for medical research, including studies involving ADHD and autism. Shares in BlinkLab (ASX:BB1) closed at AUD 0.57 on November 18, 2026, up 1.79%. The company’s 2026 disclosures included European ADHD study findings, a United States patent and academic research arrangements, with clinical validation remaining an important part of its development programme.

BlinkLab Business and Operations

BlinkLab develops smartphone-based neurobehavioural assessments designed to support research into conditions including autism and attention-deficit/hyperactivity disorder. Its work combines app-delivered stimuli with measurement and analysis of behavioural responses. The software-led platform is being studied across different conditions, meaning findings in one disorder cannot automatically establish performance in another.

BlinkLab 2026 Company Updates

In August 2026 BlinkLab described results from a European ADHD digital biomarker study, reporting sensitivity of 82% and specificity of 83% in that study. These are study-specific measures, not evidence that a diagnostic test has obtained Marketing authorisation. The reported ADHD sensitivity and specificity relate to the company’s European study; reproducibility in other settings remains a distinct question.

BlinkLab Financial and Operational Context

In June 2026 BlinkLab announced a United States patent relating to its remote neurobehavioural testing platform. Its 2026 releases also described an Ecuador multicentre autism and sensorimotor study, a research agreement with Erasmus University Medical Center, and the September appointment of Dr Raphael Bernier as a non-executive director. The patent and academic arrangements are separate developments: intellectual-property protection is not itself a clinical validation or financial milestone.

Industry Conditions and Key Risks

Clinical validation, reproducibility across populations, regulatory requirements and adoption by clinicians remain distinct hurdles. A research partnership, patent or encouraging study result does not by itself establish revenue, reimbursement or regulatory clearance. Clinical validation, physician adoption and any regulatory requirements will need to be addressed separately before broad diagnostic use can be inferred.

What to Watch Next

Further disclosures on autism-focused research and the Ecuador multicentre study can help clarify the breadth of the company’s validation programme. Readers can also monitor whether the Erasmus research arrangement produces publishable findings, whether additional independent datasets confirm the reported ADHD study measures and whether regulatory engagement is disclosed. The June patent protects intellectual property but does not resolve validation or reimbursement requirements. Later cash-flow reports can indicate the resources being used to pursue these activities.

Key Insights

BlinkLab (ASX:BB1) reported an ADHD digital biomarker study, a United States patent and research collaborations during 2026. The reported sensitivity and specificity apply to the cited study, not to a generally approved diagnostic product. The next meaningful evidence will concern independent validation, any regulatory pathway described by the company and the financial resources required to continue research.